Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults ...

We chase the miracles of science to improve people’s lives. But we can’t do it alone. We work closely with healthcare professionals, patient advocates, governments and industry so we can have the ...

Third quarter 2024 results were reviewed by management during a conference call with the financial community on Friday October 25, 2024. The presentation was followed by a Q&A session. We’re proud to ...

ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients New analysis from the IMROZ phase 3 study of Sarclisa-VRd demonstrated higher and ...

The www.sanofi.com website (hereinafter the “site”) is owned and operated by SANOFI WINTHROP INDUSTRIE, belonging to Groupe Sanofi. The presentation and each of the elements, including trademarks, ...

We chase the miracles of science to improve people’s lives, and sometimes that means starting over with Plan B, Plan C, or even Plan Z. This film brings together the inner thoughts and ambitions of ...

We’ve been committed to the ongoing international fight against yellow fever for 70 years, delivering half a billion doses of vaccines and seeking innovations for the future. Sanofi is part of the EYE ...

Established in Australia in 1980, with a global heritage that spans 100 years, we invest in the health of Australians by pioneering science and medicine across therapeutic areas including immunology, ...

Sanofi US (Sanofi-Aventis U.S. LLC and Sanofi US Services Inc.) respects the interest that visitors to our websites have in understanding what information is collected electronically, how it is ...

Sanofi has strong foundations in Canada going back over a century, and operates world-leading R&D and biomanufacturing facilities in Toronto. Sanofi also operates an artificial intelligence (AI) ...

Fourth quarter and full year 2023 results were reviewed by management during a live audio webcast with the financial community on February 1st, 2024. The presentation was followed by a Q&A session.

We want to build a healthier, more resilient world. We turn the impossible into the possible by discovering, developing, and delivering medicines and vaccines for millions of people around the world.